Abstract
The oncogenic cellular phenotype reflects transcriptional and post-transcriptional changes in gene expression. The popular technique of expression profiling with microarrays highlights that changes in messenger RNA levels are important determinants of oncogenicity. The idea that upregulation and downregulation of specific crucial target genes can cause cancer derives from the discovery of oncogenic transcription factors. So, how was JUN — the first oncogenic transcription factor — discovered?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lucchini, G., Hinnebusch, A. G., Chen, C. & Fink, G. R. Positive regulatory interactions of the HIS4 gene of Saccharomyces cerevisiae. Mol. Cell. Biol. 4, 1326–1333 (1984).
Thireos, G., Penn, M. D. & Greer, H. 5′ untranslated sequences are required for the translational control of a yeast regulatory gene. Proc. Natl Acad. Sci. USA 81, 5096–5100 (1984).
Hope, I. A. & Struhl, K. GCN4 protein, synthesized in vitro, binds HIS3 regulatory sequences: implications for general control of amino acid biosynthetic genes in yeast. Cell 43, 177–188 (1985).
Hope, I. A. & Struhl, K. Functional dissection of a eukaryotic transcriptional activator protein, GCN4 of yeast. Cell 46, 885–894 (1986).
Hinnebusch, A. G. A hierarchy of trans-acting factors modulates translation of an activator of amino acid biosynthetic genes in Saccharomyces cerevisiae. Mol. Cell. Biol. 5, 2349–2360 (1985).
Hinnebusch, A. G. The general control of amino acid biosynthetic genes in the yeast Saccharomyces cerevisiae. CRC Crit. Rev. Biochem. 21, 277–317 (1986).
Hope, I. A. & Struhl, K. GCN4, a eukaryotic transcriptional activator protein, binds as a dimer to target DNA. EMBO J. 6, 2781–2784 (1987).
Lee, W., Haslinger, A., Karin, M. & Tjian, R. Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40. Nature 325, 368–372 (1987).
Lee, W., Mitchell, P. & Tjian, R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 49, 741–752 (1987).
Angel, P. et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49, 729–739 (1987).
Pulciani, S., Santos, E., Lauver, A. V., Long, L. K. & Barbacid, M. Transforming genes in human tumors. J. Cell. Biochem. 20, 51–61 (1982).
Der, C. J., Krontiris, T. G. & Cooper, G. M. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl Acad. Sci. USA 79, 3637–3640 (1982).
Parada, L. F., Tabin, C. J., Shih, C. & Weinberg, R. A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297, 474–478 (1982).
Maki, Y., Bos, T. J., Davis, C., Starbuck, M. & Vogt, P. K. Avian sarcoma virus 17 carries the Jun oncogene. Proc. Natl Acad. Sci. USA 84, 2848–2852 (1987).
Vogt, P. K., Bos, T. J. & Doolittle, R. F. Homology between the DNA-binding domain of the GCN4 regulatory protein of yeast and the carboxyl-terminal region of a protein coded for by the oncogene jun. Proc. Natl Acad. Sci. USA 84, 3316–3319 (1987).
Struhl, K. The DNA-binding domains of the jun oncoprotein and the yeast GCN4 transcriptional activator protein are functionally homologous. Cell 50, 841–846 (1987).
Bohmann, D. et al. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1. Science 238, 1386–1392 (1987).
Angel, P. et al. Oncogene jun encodes a sequence-specific trans-activator similar to AP-1. Nature 332, 166–171 (1988).
Curran, T. & Teich, N. M. Candidate product of the FBJ murine osteosarcoma virus oncogene: characterization of a 55,000-dalton phosphoprotein. J. Virol. 42, 114–122 (1982).
Curran, T., Peters, G., Van Beveren, C., Teich, N. M. & Verma, I. M. FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. J. Virol. 44, 674–682 (1982).
Curran, T. & Teich, N. M. Identification of a 39,000-dalton protein in cells transformed by the FBJ murine osteosarcoma virus. Virology 116, 221–235 (1982).
Rauscher, F. J., Sambucetti, L. C., Curran, T., Distel, R. J. & Spiegelman, B. M. Common DNA binding site for Fos protein complexes and transcription factor AP-1. Cell 52, 471–480 (1988).
Franza, B. R. Jr, Rauscher, F. J., Josephs, S. F. & Curran, T. The Fos complex and Fos-related antigens recognize sequence elements that contain AP-1 binding sites. Science 239, 1150–1153 (1988).
Rauscher, F. J. et al. Fos-associated protein p39 is the product of the jun proto-oncogene. Science 240, 1010–1016 (1988).
Sassone-Corsi, P., Lamph, W. W., Kamps, M. & Verma, I. M. fos-associated cellular p39 is related to nuclear transcription factor AP-1. Cell 54, 553–560 (1988).
Landschulz, W. H., Johnson, P. F. & McKnight, S. L. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 240, 1759–1764 (1988).
O'Shea, E. K., Rutkowski, R. & Kim, P. S. Mechanism of specificity in the Fos–Jun oncoprotein heterodimer. Cell 68, 699–708 (1992).
O'Shea, E. K., Rutkowski, R., Stafford, W. F. & Kim, P. S. Preferential heterodimer formation by isolated leucine zippers from fos and jun. Science 245, 646–648 (1989).
Gentz, R., Rauscher, F. J., Abate, C. & Curran, T. Parallel association of Fos and Jun leucine zippers juxtaposes DNA binding domains. Science 243, 1695–1699 (1989).
Hai, T. & Curran, T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc. Natl Acad. Sci. USA 88, 3720–3724 (1991).
Ivashkiv, L. B. et al. mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element. Mol. Cell. Biol. 10, 1609–1621 (1990).
Benbrook, D. M. & Jones, N. C. Heterodimer formation between CREB and JUN proteins. Oncogene 5, 295–302 (1990).
Sassone-Corsi, P., Ransone, L. J., Lamph, W. W. & Verma, I. M. Direct interaction between fos and jun nuclear oncoproteins: role of the 'leucine zipper' domain. Nature 336, 692–695 (1988).
Rauscher, F. J., Voulalas, P. J., Franza, B. R. Jr & Curran, T. Fos and Jun bind cooperatively to the AP-1 site: reconstitution in vitro. Genes Dev. 2, 1687–1699 (1988).
Halazonetis, T. D., Georgopoulos, K., Greenberg, M. E. & Leder, P. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities. Cell 55, 917–924 (1988).
Turner, R. & Tjian, R. Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFos–cJun heterodimers. Science 243, 1689–1694 (1989).
Ransone, L. J., Visvader, J., Lamph, W. W., Sassone-Corsi, P. & Verma, I. M. fos and jun interaction: the role of the leucine zipper. Int. J. Cancer Suppl. 4, 10–21 (1989).
Kouzarides, T. & Ziff, E. Leucine zippers of fos, jun and GCN4 dictate dimerization specificity and thereby control DNA binding. Nature 340, 568–571 (1989).
Angel, P., Smeal, T., Meek, J. & Karin, M. Jun and v-jun contain multiple regions that participate in transcriptional activation in an interdependent manner. New Biol. 1, 35–43 (1989).
Nakabeppu, Y. & Nathans, D. The basic region of Fos mediates specific DNA binding. EMBO J. 8, 3833–3841 (1989).
Smeal, T., Angel, P., Meek, J. & Karin, M. Different requirements for formation of Jun:Jun and Jun:Fos complexes. Genes Dev. 3, 2091–2100 (1989).
Ryder, K., Lau, L. F. & Nathans, D. A gene activated by growth factors is related to the oncogene v-jun. Proc. Natl Acad. Sci. USA 85, 1487–1491 (1988).
Nakabeppu, Y., Ryder, K. & Nathans, D. DNA binding activities of three murine Jun proteins: stimulation by Fos. Cell 55, 907–915 (1988).
Hirai, S. I., Ryseck, R. P., Mechta, F., Bravo, R. & Yaniv, M. Characterization of junD: a new member of the jun proto-oncogene family. EMBO J. 8, 1433–1439 (1989).
Cohen, D. R. & Curran, T. fra-1: a serum-inducible, cellular immediate-early gene that encodes a fos-related antigen. Mol. Cell. Biol. 8, 2063–2069 (1988).
Foletta, V. C. et al. Cloning and characterisation of the mouse fra2 gene. Oncogene 9, 3305–3311 (1994).
Zerial, M. et al. The product of a novel growth factor activated gene, fos B, interacts with JUN proteins enhancing their DNA binding activity. EMBO J. 8, 805–813 (1989).
Glover, J. N. & Harrison, S. C. Crystal structure of the heterodimeric bZIP transcription factor c-Fos–c-Jun bound to DNA. Nature 373, 257–261 (1995).
Hilberg, F., Aguzzi, A., Howells, N. & Wagner, E. F. c-Jun is essential for normal mouse development and hepatogenesis. Nature 365, 179–181 (1993).
Hilberg, F. & Wagner, E. F. Embryonic stem (ES) cells lacking functional c-jun: consequences for growth and differentiation, AP-1 activity and tumorigenicity. Oncogene 7, 2371–2380 (1992).
Wang, Z. Q. et al. Bone and haematopoietic defects in mice lacking c-fos. Nature 360, 741–745 (1992).
Pulverer, B. J. et al. Co-purification of mitogen-activated protein kinases with phorbol ester-induced c-Jun kinase activity in U937 leukaemic cells. Oncogene 8, 407–415 (1993).
Hibi, M., Lin, A., Smeal, T., Minden, A. & Karin, M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7, 2135–2148 (1993).
Derijard, B. et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76, 1025–1037 (1994).
Bos, T. J. et al. Efficient transformation of chicken embryo fibroblasts by c-Jun requires structural modification in coding and noncoding sequences. Genes Dev. 4, 1677–1687 (1990).
Adler, V., Polotskaya, A., Wagner, F. & Kraft, A. S. Affinity-purified c-Jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity. J. Biol. Chem. 267, 17001–17005 (1992).
Adler, V., Unlap, T. & Kraft, A. S. A peptide encoding the c-Jun delta domain inhibits the activity of a c-jun amino-terminal protein kinase. J. Biol. Chem. 269, 11186–11191 (1994).
Dai, T. et al. Stress-activated protein kinases bind directly to the delta domain of c-Jun in resting cells: implications for repression of c-Jun function. Oncogene 10, 849–855 (1995).
Black, E. J., Catling, A. D., Woodgett, J. R., Kilbey, A. & Gillespie, D. A. Transcriptional activation by the v-Jun oncoprotein is independent of positive regulatory phosphorylation. Oncogene 9, 2363–2368 (1994).
Hussain, S., Kilbey, A. & Gillespie, D. A. v-Jun represses c-jun proto-oncogene expression in vivo through a 12-O-tetradecanoylphorbol-13-acetate-responsive element in the proximal gene promoter. Cell Growth Differ. 9, 677–686 (1998).
Kilbey, A., Black, E. J., Unlu, M. & Gillespie, D. A. The v-Jun oncoprotein replaces p39 c-Jun as the predominant AP-1 constituent in ASV17-transformed fibroblasts: implications for SAPK/JNK-mediated signal transduction. Oncogene 12, 2409–2418 (1996).
May, G. H., Allen, K. E., Clark, W., Funk, M. & Gillespie, D. A. Analysis of the interaction between c-Jun and c-Jun N-terminal kinase in vivo. J. Biol. Chem. 273, 33429–33435 (1998).
van Dam, H. & Castellazzi, M. Distinct roles of Jun:Fos and Jun:ATF dimers in oncogenesis. Oncogene 20, 2453–2464 (2001).
Vogt, P. K. Jun, the oncoprotein. Oncogene 20, 2365–2377 (2001).
Stam, K. et al. Evidence of a new chimeric BCR/c-ABL mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N. Engl. J. Med. 313, 1429–1433 (1985).
Kakizuka, A. et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR α with a novel putative transcription factor, PML. Cell 66, 663–674 (1991).
Galili, N. et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nature Genet. 5, 230–235 (1993).
Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. C. p53 mutations in human cancers. Science 253, 49–53 (1991).
Acknowledgements
Work of the author is supported by grants from the National Cancer Institute. This is manuscript number MEM 14965 of The Scripps Research Institute.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vogt, P. Fortuitous convergences: the beginnings of JUN. Nat Rev Cancer 2, 465–469 (2002). https://doi.org/10.1038/nrc818
Issue Date:
DOI: https://doi.org/10.1038/nrc818
This article is cited by
-
Andrographolide inhibits Burkitt’s lymphoma by binding JUN and CASP3 proteins
Cancer Chemotherapy and Pharmacology (2023)
-
An Insight into Reprogramming Barriers to iPSC Generation
Stem Cell Reviews and Reports (2020)
-
Differential responses of epithelial cells from urinary and biliary tract to eggs of Schistosoma haematobium and S. mansoni
Scientific Reports (2019)
-
MiR-760 suppresses human colorectal cancer growth by targeting BATF3/AP-1/cyclinD1 signaling
Journal of Experimental & Clinical Cancer Research (2018)
-
Special role of JUN in papillary thyroid carcinoma based on bioinformatics analysis
World Journal of Surgical Oncology (2017)